Regulus Therapeutics to Attend Two Healthcare Investment Conferences - July 09, 2024

SAN DIEGO, July 9, 2024 -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company dedicated to the discovery and development of innovative medicines targeting microRNAs, announced its participation in several upcoming investor conferences. This includes the H.C. Wainwright Third Annual Kidney Virtual Conference and the JonesHealthcare Seaside Summit.

The H.C. Wainwright Third Annual Kidney Virtual Conference will feature a fireside chat with Regulus on Monday, July 15, 2024, at 10:30 a.m. ET (7:30 a.m. PT). Later that same day, at 4:00 p.m. ET (1:00 p.m. PT), Regulus will present at the JonesHealthcare Seaside Summit. During these events, the company will provide a corporate update and share new analyses from the third cohort of patients in its ongoing Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429. This trial focuses on treating autosomal dominant polycystic kidney disease (ADPKD).

The live events and replays of these presentations will be accessible under the "Events and Presentations" section of Regulus' website. These replays will remain available for 90 days following the presentation date.

About Regulus:
Regulus Therapeutics Inc. (Nasdaq: RGLS) is headquartered in San Diego, CA. The company specializes in the discovery and development of innovative medicines targeting microRNAs. By leveraging its expertise in oligonucleotide drug discovery and development, Regulus has built a promising pipeline supported by a strong intellectual property portfolio in the microRNA field.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!